Epidemiology and pathophysiology of male sexual dysfunction

Kaminetsky, Jed

doi:10.1038/ijir.2008.16

Cited by 32 publications

(21 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, beside organic disorders, many different drugs can cause ED by affecting sexual hormone levels, neurotransmission, or blood circulation. Among them, antidepressants (especially those acting on the serotoninergic pathways), neuroleptics, and antihypertensives are the drugs most often associated to SD, including ED [25].…”

Section: Discussionmentioning

confidence: 99%

Sexual Dysfunction Induced by Intrathecal Baclofen Administration: Is This the Price to Pay for Severe Spasticity Management?

Calabrò

D’Aleo

Sessa

et al. 2014

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Sexual Dysfunction Induced by Intrathecal Baclofen Administration: Is This the Price to Pay for Severe Spasticity Management?

Calabrò

D’Aleo

Sessa

et al. 2014

The Journal of Sexual Medicine

View full text Add to dashboard Cite

“…Accordingly, ED could be attributed to any combination of hormonal deficiency, arterial insufficiency, neurological impairment, adverse reaction to drugs, systemic chronic disease, psychological disturbance, or cavernosal defects [47]. However, a recent hemodynamic study of fresh human cadavers indicated that a rigid erection was unequivocally attainable after erection-related veins were removed in all subjects – despite the fact that their sinusoidal tissues were dead [48].…”

Section: Pathophysiology Of Erectile Dysfunctionmentioning

confidence: 99%

physiology: Clinical implications for physicians and surgeons

et al. 2012

View full text Add to dashboard Cite

SummaryRecent studies substantiate a model of the tunica albuginea of the corpora cavernosa as a bi-layered structure with a 360° complete inner circular layer and a 300° incomplete outer longitudinal coat spanning from the bulbospongiosus and ischiocavernosus proximally and extending continuously into the distal ligament within the glans penis. The anatomical location and histology of the distal ligament invites convincing parallels with the quadrupedal os penis and therefore constitutes potential evidence of the evolutionary process. In the corpora cavernosa, a chamber design is responsible for facilitating rigid erections. For investigating its venous factors exclusively, hemodynamic studies have been performed on both fresh and defrosted human male cadavers. In each case, a rigid erection was unequivocally attainable following venous removal. This clearly has significant ramifications in relation to penile venous surgery and its role in treating impotent patients. One deep dorsal vein, 2 cavernosal veins and 2 pairs of para-arterial veins (as opposed to 1 single vein) are situated between Buck’s fascia and the tunica albuginea. These newfound insights into penile tunical, venous anatomy and erection physiology were inspired by and, in turn, enhance clinical applications routinely encountered by physicians and surgeons, such as penile morphological reconstruction, penile implantation and penile venous surgery.

show abstract

“…Until the 1980s, the treatment options were limited to psychosexual therapy and placement of penile implants, and through that time it was believed that ED was primarily due to psychogenic causes. With the introduction of prostaglandin intracavernosal injections in the late 1980s, the vasculogenic etiologies of ED became better understood, and the connection between late onset hypogonadism and ED led to research elucidating the hormonal etiologies of the condition (Kaminetsky 2008). Finally, the new oral treatment with PDE5 inhibitors has led to the current understanding of the pathophysiology of ED as well as the physiology of erection.…”

Section: Erectile Dysfunctionmentioning

confidence: 99%

Tadalafil in the treatment of erectile dysfunction

Coward¹,

Carson²

2008

TCRM

106

View full text Add to dashboard Cite

Abstract:The treatment for erectile dysfunction (ED) was revolutionized with the development of phosphodiesterase type 5 (PDE5) inhibitors. Tadalafi l (Cialis ® ; Eli Lilly and Company, Indianapolis, IN, USA) is the newest and most versatile PDE5 inhibitor in the clinical armamentarium for the treatment of ED. Its most unique characteristic is its long half-life of 17.5 hours, which lends itself to a longer therapeutic window with on-demand dosing and effective steadystate plasma concentrations with once-daily dosing. Clinical trials have proven its safety and effi cacy with both dosing strategies for all severities and etiologies of ED, including diffi cultto-treat ED. This thorough review will discuss ED, the physiology of penile erection and the role of PDE5, and all aspects of tadalafi l, from its development, through its pharmacology, to its latest clinical studies and indications.

show abstract

Epidemiology and pathophysiology of male sexual dysfunction

Cited by 32 publications

References 50 publications

Sexual Dysfunction Induced by Intrathecal Baclofen Administration: Is This the Price to Pay for Severe Spasticity Management?

Sexual Dysfunction Induced by Intrathecal Baclofen Administration: Is This the Price to Pay for Severe Spasticity Management?

physiology: Clinical implications for physicians and surgeons

Tadalafil in the treatment of erectile dysfunction

Contact Info

Product

Resources

About